List of Lazanda drug patents

Lazanda is owned by Btcp Pharma.

Lazanda contains Fentanyl Citrate.

Lazanda has a total of 5 drug patents out of which 0 drug patents have expired.

Lazanda was authorised for market use on 30 June, 2011.

Lazanda is available in spray, metered;nasal dosage forms.

Lazanda can be used as management of breakthrough pain in patients with cancer.

The generics of Lazanda are possible to be released after 26 January, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9078814 BTCP PHARMA Intranasal spray device containing pharmaceutical composition
Jan, 2024

(11 months from now)

US9814705 BTCP PHARMA Intranasal spray device containing pharmaceutical composition
Jan, 2024

(11 months from now)

US8889176 BTCP PHARMA Method of managing or treating pain
Jan, 2024

(11 months from now)

US8216604 BTCP PHARMA Method of managing or treating pain
Oct, 2024

(1 year, 8 months from now)

US9731869 BTCP PHARMA Container
Jan, 2032

(8 years from now)

Drugs and Companies using FENTANYL CITRATE ingredient

Market Authorisation Date: 30 June, 2011

Treatment: Management of breakthrough pain in patients with cancer

Dosage: SPRAY, METERED;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic